Trending Down-0.0300 (-0.2453%)
  • Bid / Lots
    12.4200/ 1
  • Ask / Lots
    18.7500/ 1
  • Open / Previous Close
    12.2300 / 12.2300
  • Day Range
    Low 12.0000
    High 12.2300
  • 52 Week Range
    Low 5.8500
    High 17.4400
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 12.23
09:32 ET35312.23
09:59 ET80012.05
10:01 ET90012.12
10:03 ET142112
10:08 ET50012.01
10:10 ET64512
10:12 ET10012.025
10:21 ET10012.015
10:30 ET70012.08
10:46 ET20012.08
10:55 ET92612.1
10:57 ET10012.14
11:02 ET79612.1
11:09 ET97512.19
11:11 ET10012.2
11:13 ET84912.13
11:18 ET160412.12
11:26 ET40012.14
11:36 ET10012.21
11:40 ET10012.17
11:47 ET10012.185
12:00 ET10012.14
12:07 ET10012.14
12:14 ET10012.16
12:54 ET10012.22
12:56 ET10012.2242
01:03 ET10012.19
01:06 ET30012.19
01:10 ET10012.2
01:17 ET10012.2
01:35 ET10012.21
01:50 ET10012.16
01:53 ET60412.15
02:02 ET10012.13
02:11 ET20012.11
02:18 ET20012.15
02:31 ET10012.14
02:33 ET85012.1246
02:40 ET10012.13
02:56 ET20012.09
03:09 ET10012.11
03:23 ET30012.1
03:34 ET10012.1
03:39 ET22712.15
03:41 ET20012.16
03:50 ET30012.14
03:52 ET10012.13
03:54 ET10012.11
03:56 ET72312.14
03:57 ET40012.14
03:59 ET155112.2
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMLYS
Mineralys Therapeutics Inc
United StatesOCS
Oculis Holding AG
United StatesPHAT
Phathom Pharmaceuticals Inc
United StatesMNMD
Mind Medicine (MindMed) Inc
United StatesERAS
Erasca Inc
United StatesLXRX
Lexicon Pharmaceuticals Inc
As of 2024-05-27

Company Information

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone. The Company’s product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) that the Company is initially developing for the treatment of patients with uncontrolled hypertension (uHTN). Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. The Company completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uHTN. In addition to hypertension, the Company intends to develop lorundrostat for the treatment of chronic kidney disease (CKD).

Contact Information

150 N. Radnor Chester Road, Suite F200RADNOR, PA, United States 19087


Executive Chairman of the Board, Founder
Brian Slingsby
Chief Executive Officer, Director
Jon Congleton
Chief Financial Officer, Company Secretary
Adam Levy
Chief Medical Officer
David Rodman
Chief Business Officer
Minji Kim

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.